Loading clinical trials...

COMPLETED

Morbidity, Mortality And Risk Factors of Mpox in HIV Negative High Risk Sexual Health Clinic Attenders and People Living With HIV

NCT05965427•NEAT ID Foundation

Summary

This data collection study aims to describe and compare the outcomes of Mpox on people living with HIV (PLHIV) and HIV-negative individuals who are on pre-exposure prophylaxis (PrEP). The study also aims to identify risk factors for specific Mpox outcomes.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Diagnosis of MPX was more than 90 days prior to data collection
•Confirmed MPX infection by documented PCR testing of lesions between 1st May 2022 to 1st December 2023
•At least 18 years of age
•Cases (PLWHIV + MPX) i) Documented HIV-1 infection
•Cases (PrEP users + MPX) i) Attended a clinic to receive PrEP

Exclusion Criteria

•MPX diagnosed based on clinical criteria only
•MPX diagnosis was within the last 90 days

Locations (9)

Hôpital Bichat Claude Bernard

Paris, France

Hôpital Pitié-Salpêtrière

Paris, France

Euroguidelines

Warsaw, Poland

Hospital Clinic de Barcelona

Barcelona, Spain

Hospital Universitari Germans Trias I Pujol

Barcelona, Spain

Hospital Universitari Vall d'Hebron

Barcelona, Spain

Hospital San Carlos

Madrid, Spain

Hospital Universitario La Paz

Madrid, Spain

Chelsea and Westminster Hospital

London, United Kingdom

Key Dates

Start Date

December 1, 2023

Primary Completion Date

May 7, 2025

Completion Date

May 7, 2025

Last Updated

August 13, 2025

Enrollment

2,000

ACTUAL participants

Conditions

MonkeypoxHIV Coinfection

Interventions

No intervention

OTHER

A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa

NCT07379580

Mpox (Monkeypox)Smallpox+1 more

View study

RECRUITINGNA

Closing -TB GAPs - for People Living With HIV: TB Guidance for Adaptable Patient-Centered Service

NCT05342064

TuberculosisHIV Coinfection+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 13, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Morbidity, Mortality And Risk Factors of Mpox in HIV Negative High Risk Sexual Health Clinic Attenders and People Living With HIV

Inclusion Criteria

Exclusion Criteria

A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa

Closing -TB GAPs - for People Living With HIV: TB Guidance for Adaptable Patient-Centered Service

Epidemiological and Clinical Characteristics of Human Mpox Outbreak in Equateur Province in the Democratic Republic of Congo (Part2)

Epidemiological and Clinical Characteristics of Human Mpox Outbreak in Equateur Province in the Democratic Republic of Congo (Part3)

Optimizing Malaria Treatment for HIV-Malaria Co-infected Individuals